Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Kulke

Showing results (71-80 of 182) with videos related to

Pageof 19
Sort By:
Advances in Therapy|December 23, 2017
Development of a Framework Based on Reflective MCDA to Support Patient-Clinician Shared Decision-Making: The Case of the Management of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) in the United StatesMonika Wagner, Dima Samaha, Hanane Khoury, et al.
Lung Cancer (Amsterdam, Netherlands)|September 15, 2014
Chemotherapy for locally advanced and metastatic pulmonary carcinoid tumorsCurtis R Chong, Lori J Wirth, Mizuki Nishino, et al.
The Oncologist|February 10, 2017
Association Between Tumor Progression Endpoints and Overall Survival in Patients with Advanced Neuroendocrine TumorsMonica Ter-Minassian, Sui Zhang, Nichole V Brooks, et al.
Endocrine-Related Cancer|June 28, 2012
Phase I study of pasireotide (SOM 230) and everolimus (RAD001) in advanced neuroendocrine tumorsJennifer A Chan, David P Ryan, Andrew X Zhu, et al.
Cancer|March 8, 2017
Retrospective review of serotonergic medication tolerability in patients with neuroendocrine tumors with biochemically proven carcinoid syndromeDiana D Shi, David P Yuppa, Trevor Dutton, et al.
Journal of Nuclear Medicine Technology|August 5, 2018
Guidance on <sup>177</sup>Lu-DOTATATE Peptide Receptor Radionuclide Therapy from the Experience of a Single Nuclear Medicine DivisionAmanda Abbott, Christopher G Sakellis, Eric Andersen, et al.
Virchows Archiv : an International Journal of Pathology|March 21, 2007
CpG island methylation, response to combination chemotherapy, and patient survival in advanced microsatellite stable colorectal carcinomaShuji Ogino, Jeffrey A Meyerhardt, Takako Kawasaki, et al.
Cancer Investigation|October 10, 2003
A phase II study of modified deGramont 5-fluorouracil, leucovorin, and oxaliplatin in previously treated patients with metastatic colorectal cancerDavid P Ryan, Jeffrey W Clark, Matthew H Kulke, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 28, 2009
Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904Matthew H Kulke, Margaret A Tempero, Donna Niedzwiecki, et al.
Carcinogenesis|September 11, 2008
Genetic polymorphisms of VEGF, interactions with cigarette smoking exposure and esophageal adenocarcinoma riskRihong Zhai, Geoffrey Liu, Kofi Asomaning, et al.
Pageof 19

Showing results (71-80 of 182) with videos related to

Sort By:
Pageof 19
Advances in Therapy|December 23, 2017
Development of a Framework Based on Reflective MCDA to Support Patient-Clinician Shared Decision-Making: The Case of the Management of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) in the United StatesMonika Wagner, Dima Samaha, Hanane Khoury, et al.
Lung Cancer (Amsterdam, Netherlands)|September 15, 2014
Chemotherapy for locally advanced and metastatic pulmonary carcinoid tumorsCurtis R Chong, Lori J Wirth, Mizuki Nishino, et al.
The Oncologist|February 10, 2017
Association Between Tumor Progression Endpoints and Overall Survival in Patients with Advanced Neuroendocrine TumorsMonica Ter-Minassian, Sui Zhang, Nichole V Brooks, et al.
Endocrine-Related Cancer|June 28, 2012
Phase I study of pasireotide (SOM 230) and everolimus (RAD001) in advanced neuroendocrine tumorsJennifer A Chan, David P Ryan, Andrew X Zhu, et al.
Cancer|March 8, 2017
Retrospective review of serotonergic medication tolerability in patients with neuroendocrine tumors with biochemically proven carcinoid syndromeDiana D Shi, David P Yuppa, Trevor Dutton, et al.
Journal of Nuclear Medicine Technology|August 5, 2018
Guidance on <sup>177</sup>Lu-DOTATATE Peptide Receptor Radionuclide Therapy from the Experience of a Single Nuclear Medicine DivisionAmanda Abbott, Christopher G Sakellis, Eric Andersen, et al.
Virchows Archiv : an International Journal of Pathology|March 21, 2007
CpG island methylation, response to combination chemotherapy, and patient survival in advanced microsatellite stable colorectal carcinomaShuji Ogino, Jeffrey A Meyerhardt, Takako Kawasaki, et al.
Cancer Investigation|October 10, 2003
A phase II study of modified deGramont 5-fluorouracil, leucovorin, and oxaliplatin in previously treated patients with metastatic colorectal cancerDavid P Ryan, Jeffrey W Clark, Matthew H Kulke, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 28, 2009
Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904Matthew H Kulke, Margaret A Tempero, Donna Niedzwiecki, et al.
Carcinogenesis|September 11, 2008
Genetic polymorphisms of VEGF, interactions with cigarette smoking exposure and esophageal adenocarcinoma riskRihong Zhai, Geoffrey Liu, Kofi Asomaning, et al.
Pageof 19